InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Core Insights - InMed Pharmaceuticals Inc. has confirmed INM-901 as an oral formulation for its Alzheimer's disease development programs [1] - Recent preclinical studies show that INM-901 can achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection [2][3] - The oral formulation of INM-901 maintains similar drug exposure levels in the brain over a 24-hour period as compared to IP delivery [3] Company Developments - Michael Woudenberg, COO of InMed, expressed excitement over the data confirming that INM-901 can cross the blood-brain barrier as an oral formulation, highlighting its advantages for Alzheimer's treatment [4] - The company is conducting further studies on drug metabolism, dose-ranging, and pharmacokinetics to support an IND submission [6] Market Reaction - Following the announcement, INM stock experienced a significant increase of 241.8%, reaching $0.51 [6]